General Newsroom Hero 1920x480 (4:1)
Our Work

Latham & Watkins Advises Bioventus in its Initial Public Offering

February 11, 2021
A bicoastal deal team advises the life sciences company in the approximately US$104 million offering.

Bioventus Inc. has announced the pricing of its initial public offering of 8 million shares of Class A common stock at a public offering price of US$13 per share. The Company’s Class A common stock began trading on the Nasdaq Global Select Market under the symbol “BVS.”

Latham & Watkins LLP represents Bioventus, Inc. in the offering with a corporate team led by Boston/New York partner Wesley Holmes and Orange County/New York partner Charles Ruck, with associates Katie Lovejoy, Jessica Lim, Jonathan Hernandez, and Hera Liao. Advice was also provided on tax matters by Washington, D.C. partner Andrea Ramezan-Jackson, with associate Eli McCrain; on benefits and compensation matters by New York counsel Rifka Singer, with associate Daniel Gocek; on intellectual property matters by Bay Area partner Judith Hasko, with associate Seth Appiah-Opoku; on public company representation matters by New York partner Dennis Craythorn, with associate Kate Pritchard; on FDA regulatory matters by Washington, D.C. partner Elizabeth Richards, with associate Barrett Tenbarge; and on healthcare regulatory matters by Washington, D.C. partners Stuart Kurlander and Eric Greig.